Why Statins Give Some People Muscle Pain: The SLCO1B1 Gene
If statins wreck your muscles, one gene may explain it — and there's an official, evidence-based dosing playbook around it.
Statins are among the most prescribed and most beneficial drugs in the world. But a subset of people get muscle aches on them, and for some, a single gene — SLCO1B1 — helps explain why. There's an official, evidence-based dosing guideline built around it.
The problem statins solve — and the side effect that derails it
Statins lower LDL cholesterol and prevent heart attacks and strokes. The most common reason people stop taking them is muscle-related side effects — aches, soreness, weakness (collectively "statin-associated musculoskeletal symptoms," or SAMS). In the vast majority of cases these are mild, but they're a leading cause of people quitting a medication that's actively protecting their heart. Anything that helps predict and manage them has real value.
What SLCO1B1 does
The SLCO1B1 gene codes for a transporter protein (OATP1B1) that ferries statins from the blood into the liver, where they do their work and get cleared. A common variant, rs4149056 (also written c.521T>C), reduces that transporter's function. The result: statins clear more slowly and reach higher concentrations in the bloodstream and muscles — raising the risk of muscle toxicity, most strongly demonstrated with simvastatin.
The guideline that turns genotype into action
The Clinical Pharmacogenetics Implementation Consortium (CPIC) — the main body translating pharmacogenomics into prescribing advice — has published a guideline covering SLCO1B1 (along with ABCG2 and CYP2C9) and statins. The updated guidance replaced the earlier simvastatin-only version and now spans multiple statins. In broad terms:
- People with decreased or poor SLCO1B1 transporter function are at higher risk of muscle symptoms, especially at higher simvastatin doses.
- For those individuals, the guidance supports a lower dose of the higher-risk statin, or choosing an alternative statin less dependent on this transporter.
- The goal is to keep people on effective cholesterol-lowering therapy by picking a statin and dose they can tolerate — rather than abandoning statins altogether.
Important honesty about what this does and doesn't explain
Not all statin muscle pain is genetic, and SLCO1B1 doesn't explain every case. The evidence is strongest for simvastatin; it's weaker or more variable for other statins. Many people with the higher-risk genotype tolerate statins fine, and many people with muscle symptoms have a completely normal SLCO1B1 result. Genetics is one useful input, not a full explanation of a complex, sometimes subjective symptom.
How genome data helps
SLCO1B1 status is exactly the kind of pharmacogenomic information a whole genome sequence captures once and keeps forever. Rather than testing reactively after you've already had a bad experience, having your genotype on file means the information is available the moment a statin is being considered. Bring it to your prescriber — they can factor it into which statin and dose to start with.
Know Your Statin Genetics Before You Need Them
A whole genome sequence reads SLCO1B1 (and other pharmacogenes) once and for life. Share the result with your doctor so statin choice can be personalized from the start — not after a bad reaction.
Get 10% Off Whole Genome Sequencing → Use code GENOME at checkout · Italian lab · Full 30x WGS · You keep the raw dataWhat to do
- Never stop a prescribed statin on your own based on a genetic result — talk to your prescriber first.
- Report muscle symptoms to your doctor; they can adjust drug or dose.
- Bring your SLCO1B1 result to appointments where statins are discussed.
- Remember the aim: staying on effective, tolerable cholesterol treatment.
This article is for general educational purposes only and is not medical advice. Genetic results should be interpreted with a qualified healthcare provider or genetic counselor. Do not start, stop, or change any medication or treatment based on this article.